Form 4 Filing for Avalo Therapeutics, Inc.

This filing details a Form 4 submission for Avalo Therapeutics, Inc. (AVTX) concerning a transaction on May 21, 2026. The transaction involved 100,200 shares of Common Stock, acquired under transaction code "A" with a price of $0.00 per share. Following this transaction, the post-transaction shares owned are 190,314. The shares were acquired through performance stock units (PSUs) granted on August 19, 2025, which vested on May 21, 2026, upon the achievement of performance goals. These PSUs are subject to a vesting date of August 19, 2028, contingent upon the reporting person's continued service. The reporting person is NEIL GARRY ARTHUR, identified as the Chief Executive Officer and a director of the company, with ownership designated as direct.